Prinz_supplement_Layout 1 16/09/2009 12:37 Page 6
Psoriasis
1. Gelfand JM, Neimann AL, Shin DB, et al., Risk of 22. Wallis RS, Broder M, Wong J, et al., Reactivation of latent patients treated with anti-TNF therapy and methotrexate,
myocardial infarction in patients with psoriasis, JAMA, granulomatous infections by infliximab, Clin Infect Dis, Abstract presented at EULAR, Austria, 8–11 June 2005.
2006;296(14):1735–41. 2005;41(Suppl. 3):S194–8. 40. Sattar N, Crompton P, Cherry L, et al., Effects of tumor
2. Gelfand JM, Troxel AB, Lewis JD, et al., The risk of mortality 23. Dixon WG, Watson K, Lunt M, et al., British Society for necrosis factor blockade on cardiovascular risk factors in
in patients with psoriasis: results from a population-based Rheumatology Biologics Register. Rates of serious psoriatic arthritis: a double-blind, placebo-controlled
study, Arch Dermatol, 2007;143(12):1493–9. infection, including site-specific and bacterial intracellular study, Arthr Rheum, 2007;56:831–9.
3. Prinz JC, The role of T cells in psoriasis, J Eur Acad Dermatol infection, in rheumatoid arthritis patients receiving anti- 41. Strober BE, Teller C, Yamauchi P, et al., Effects of
Venereol, 2003;17(3):257–70. tumor necrosis factor therapy: results from the British etanercept on C-reactive protein levels in psoriasis and
4. Boehncke W-H, Sterry W, Psoriasis – a systemic Society for Rheumatology Biologics Register, Arthritis psoriatic arthritis, Br J Dermatol, 2008;159:322–30.
inflammatory disorder: clinic, pathogenesis and therapeutic Rheum, 2006;54(8):2368–76. 42. Watcher K, Adalimumab interruption leads to poor
perspectives, J Dtsch Dematol Ges, 2009; in press. 24. Magliocco MA, Gottlieb AB, Etanercept therapy for re-treatment response, Skin & Allergy News, 2008;39(11):50.
5. Gisondi P, Girolomoni G, Biologic therapies in psoriasis: A patients with psoriatic arthritis and concurrent hepatitis C 43. Papp K, et al., Efficacy outcomes for patients with psoriasis
new therapeutic approach, Autoimmun Rev, 2007;6:515–19. virus infection:report of 3 cases, J Am Acad Dermatol, who interrupt adalimumab therapy, 17th European
6. Jullien D, Prinz JC, Langley RG, et al., T-cell modulation for 2004;51:580–84. Academy of Dermatology and Venereology (EADV)
the treatmnet of chronic plaque psoriasis with efaluzimab 25. Rokhsar C, Rabhan N, Cohen SR, Etanercept monotherapy Congress, 2008; abstract FP1384.
(Raptiva): mechanisms of action, Dermatology, 2004;208(4): for a patient with psoriasis, psoriatic arthritis, and 44. Baert F, Noman M, Vermeire S, et al., Influence of
297–306. concomitant hepatitis C infection, J Am Acad Dermatol, immunogenicity on the longterm efficacy of infliximab in
7. Ortonne JP, Prinz JC, Alefacept: a novel and sensitive 2006;54:361–2. Crohn’s disease, N Engl J Med, 2003;348:601–8.
biologic agent for the treatment of chronic plaque 26. EMEA/CHMP/20857/2009. Available at: www.emea. 45. Gottlieb AB, Evans R, Li S, et al., Infliximab induction
psoriasis, Eur J Dermatol, 2004;14(1):41–5. europa.eu/humandocs/PDFs/EPAR/raptiva/2085709en.pdf therapy for patients with severe plaque-type psoriasis: A
8. Boehncke W-H, Prinz J, Gottleib AB, Biologic therapies for 27. Gordon K, Langley R, Leonardi C, et al., Clinical response randomized,double-blind, placebo-controlled trial, J Am
psoriasis. A systematic review, J Rheumatol, 2006;33:1447–51. to adalimumab treatment in patients with moderate to Acad Dermatol, 2004;51(4):534–42.
9. Leonardi CL, Kimball AB, Papp KA, et al., Efficacy and safety severe psoriasis: Double-blind, randomized controlled trial 46. Gottlieb AB, Matheson RT, Lowe N, et al., A randomized
of ustekinumab, a human interleukin-12/23 monoclonal and open-label extension study, J Am Acad Dermatol, trial of etanercept as monotherapy for psoriasis, Arch
antibody, in patients with psoriasis: 76-week results from a 2006;55(4):598–606. Dermatol, 2003;139:1627–32.
randomized, double-blind, placebo-controlled trial 28. Langley R, Leonardi C, Toth D, Chen D, Long-term safety 47. Leonardi CL, Elewski B, Camisa C, et al., The efficacy and
(PHOENIX 1), Lancet, 2008;371(9625):1665–74. and efficacy of adalimumab in the treatment of moderate safety of etanercept in the re-treatment of psoriasis after
10. Strober BE, Siu K, Menon K, Systematic review of to severe chronic plaque psoriasis, J Am Acad Dermatol, relapse, J Am Acad Dermatol, 2004;50(S3):P146.
conventional systemic agents for psoriasis, J Rheumatol, 2005;52(3 Suppl.): poster 8. 48. Ortonne,JP, Griffiths CEM, Daudén E, et al., Efficacy and
2006;33:1442–6. 29. Tyring S, Gordon KB, Poulin Y, et al., Long-term safety and Safety of Continuous Versus Paused Etanercept Treatment
11. Leonardi CL, Efalizumab in the treatment of psoriasis, efficacy of 50 mg of etanercept twice weekly in patients in Patients With Moderate-to-Severe Psoriasis Over 54
Dermatol Ther, 2004;17:393–400. with psoriasis, Arch Dermatol, 2007;143(6):719–26. Weeks: The CRYSTEL Study, Expert Rev Dermatol,
12. Papp KA, Tyring S, Lahfa M, et al., A global phase III 30. Tyring S, Langley R, Gordon K, et al., Efficacy and safety 2008;3(6):657–65.
randomized controlled trial of etanercept in psoriasis: profiles of etanercept 50 mg twice weekly for up to 144 49. Thielen AM, Kuenzli S, Saurat J-H, Cutaneous Adverse
safety, efficacy, and effect of dose reduction, Br J Dermatol, weeks in patients with moderate to severe plaque Events of Biological Therapy for Psoriasis: Review of the
2005;152(6):1304–12. psoriasis, J Am Acad Dermatol, 2007;56:AB182. Literature, Dermatology, 2005;211:209–17.
13. Reich K, Nestle FO, Papp K, et al., Infliximab induction and 31. Papp K, Poulin Y, Bissonnette R, et al., Assessment of the 50. Brunasso AMG, Delfino C, Massone C, Efalizumab rebound
maintenance therapy for moderate-to-severe psoriasis: a Long-term Safety of Etanercept for the Treatment of response to a sequential therapy of infliximab followed by
phase III, multicentre, double-blind trial, Lancet, Psoriasis in an Adult Canadian Population, Program and efalizumab, Dermatology, 2009;218:73–4.
2005;366(9494):1367–74. abstracts of the Annual Congress of the European 51. Gottlieb AB, Gordon K, Wang A, et al., Withdrawal from
14. Menter A, Tyring SK, Gordon K, et al., Adalimumab therapy Academy of Dermatology and Venereology, Paris, France, etanercept after successful clinical response in psoriasis
for moderate to severe psoriasis: A randomized, controlled 17–20 September 2008; poster 1386. patients: disease characteristics and the durability of
phase III trial, J Am Acad Dermatol, 2008;58(1):106–15. 32. Paller AS, Siegfired EC, Langley RG, et al., Etanercept treatment response, J Am Acad Dermatol, 2004;50(S3):P146.
15. van de Kerkhof PC, Segaert S, Lahfa M, et al., Once weekly Pediatric Psoriasis Study Group. Etanercept treatment for 52. Koo J, Khera P, Update on the mechanisms and efficacy of
administration of etanercept 50 mg is efficacious and well children and adolescents with plaque psoriasis, N Eng J biological therapies for psoriasis, J Dermatol Sci, 2005;38:
tolerated in patients with moderate-to severe plaque Med, 2008;358(3):241–51. 75–87.
psoriasis: a randomized controlled trial with open-label 33. Lambert J, et al., Sustained improvements in depression 53. Lewkowicz D, Gottlieb AB, Pediatric psoriasis and psoriatic
extension, Br J Dermatol, 2008;159(5):177–85. and anxiety symptoms with etanercept therapy for up to arthritis, Dermatol Ther, 2004;17:364–75.
16. Weisenseel P, et al., Disseminated eruptive giant mollusca 54 weeks in patients with moderate to severe psoriasis: 54. Tracey D, Klareskog L, Sasso EH, et al., Tumor necrosis
contagiosa in an adult psoriasis patient during efalizumab Results of the CRYSTEL study, EADV 2008, FP1359. factor antagonist mechanisms of action: a comprehensive
therapy, Dermatology, 2005;217(1):85–6. 34. Revicki, DA, Willian NK, Menter A, et al., Relationship review, Pharmacol Ther, 2008;117(2):244–79.
17. Smith CH, Anstey AV, Barker JNWN, et al., British between clinical response to therapy and health-related 55. Weinberg JM, Buchholz R, Scheinfeld N, Evidence-based
Association of Dermatologists guidelines for use of quality of life outcomes in patients with moderate to review of Biologic Therapy for Psoriasis: Infliximab,
biological interventions in psoriasis, 2005;153(3):486–97. severe plaque psoriasis, Dermatol, 2008;216(3):260–70. Etanercept Adalimumab , Efalizumab, and Alefacept,
18. Brimhall AK, King LN, Licciardone L, et al., Safety and 35. Bos JD, de Korte J, Effects of etanercept on quality of life, Adv Stud Med, 2005;5(4):195–206.
efficacy of alefacept, efalizumab, etanercept and fatigue, and depression in psoriasis, Lancet, 2006;367:6–7. 56. Gottlieb AB, Mendelsohn A, Shen Y-K, et al., A randomized,
infliximab in treating moderate to severe plaque psoriasis: 36. Feldman SR, Gordon KB, Bala M, et al., Infliximab placebo-controlled phase 2 study of ustekinumab, a
a meta-analysis of randomized controlled trials, Br J treatment results in significant improvement in the quality human interleukin-12/23 monoclonal antibody, in psoriatic
Dermatol, 2008;159(2):274–85. of life of patients with severe psoriasis: a double blind arthritis, Program and abstracts of the American Academy
19. Lecluse LLA, Piskin G, Mekkes JR, et al., Review and expert placebo-controlled trial, Br J Dermatol, 2005;152:954–60. of Dermatology Summer Meeting, Chicago, Illinois,
opinion on prevention and treatment of infliximab-related 37. Neimann A, Shin D, Wang X, et al., Prevalence of 30 July – 3 August 2008; poster 2411.
infusion reactions, Br J Dermatol, 2008;159(3):513–26. cardiovascular risk factors in patients with psoriasis, 57. Griffiths C, Strober B, van de Kerkhof PCM, et al., A phase 3,
20. Wallis RS, Broder MS, Wong JY, et al., Granulomatous J Am Acad Dermatol, 2006;55:829–35. multicenter, randomized study comparing ustekinumab and
infectious diseases associated with tumor necrosis factor 38. Gelfand J, Berlin J, Van Voorhees A, et al., Lymphoma rates etanercept for the treatment of moderate to severe plaque
antagonists, Clin Infect Dis, 2004;38:1261–5. are low but increased in patients with psoriasis: results psoriasis, Program and abstracts of the Annual Congress of
21. Wallis RS, Broder MS, Wong JY, et al., Granulomatous from a population-based cohort study in the United the European Academy of Dermatology and Venereology,
infections due to tumor necrosis factor blockade: Kingdom, Arch Dermatol, 2003;139:1425–9. Paris, France, 17–20 September 2008; poster 1336.
correction, Clin Infect Dis, 2004;39:1254–5. 39. Michaud K, Wolfe W, Reduced Mortality among RA
6
All content in this publication is the sole property of Touch Group plc. Touch Group plc cannot guarantee the accuracy, adequacy or completeness of any information contained therein, and cannot be held responsible
for any errors or omissions, or for the results obtained from the use thereof. Where opinion is expressed, it is that of the author(s) and does not necessarily coincide with the editorial views of Touch Group plc.
Page 1  |  Page 2  |  Page 3  |  Page 4  |  Page 5  |  Page 6  |  Page 7  |  Page 8  |  Page 9  |  Page 10  |  Page 11  |  Page 12  |  Page 13  |  Page 14  |  Page 15  |  Page 16  |  Page 17  |  Page 18  |  Page 19  |  Page 20  |  Page 21  |  Page 22  |  Page 23  |  Page 24  |  Page 25  |  Page 26  |  Page 27  |  Page 28  |  Page 29  |  Page 30  |  Page 31  |  Page 32  |  Page 33  |  Page 34  |  Page 35  |  Page 36  |  Page 37  |  Page 38  |  Page 39  |  Page 40  |  Page 41  |  Page 42  |  Page 43  |  Page 44  |  Page 45  |  Page 46  |  Page 47  |  Page 48  |  Page 49  |  Page 50  |  Page 51  |  Page 52  |  Page 53  |  Page 54  |  Page 55  |  Page 56  |  Page 57  |  Page 58  |  Page 59  |  Page 60  |  Page 61  |  Page 62  |  Page 63  |  Page 64  |  Page 65  |  Page 66  |  Page 67  |  Page 68  |  Page 69  |  Page 70  |  Page 71  |  Page 72  |  Page 73  |  Page 74  |  Page 75  |  Page 76  |  Page 77  |  Page 78  |  Page 79  |  Page 80  |  Page 81  |  Page 82  |  Page 83  |  Page 84  |  Page 85  |  Page 86  |  Page 87  |  Page 88  |  Page 89  |  Page 90  |  Page 91  |  Page 92  |  Page 93  |  Page 94  |  Page 95  |  Page 96  |  Page 97  |  Page 98  |  Page 99